BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 28230065)

  • 1. In vivo evaluation of a novel format of a bivalent HER3-targeting and albumin-binding therapeutic affibody construct.
    Bass TZ; Rosestedt M; Mitran B; Frejd FY; Löfblom J; Tolmachev V; Ståhl S; Orlova A
    Sci Rep; 2017 Feb; 7():43118. PubMed ID: 28230065
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of Molecular Design on the Targeting Properties of ABD-Fused Mono- and Bi-Valent Anti-HER3 Affibody Therapeutic Constructs.
    Altai M; Leitao CD; Rinne SS; Vorobyeva A; Atterby C; Ståhl S; Tolmachev V; Löfblom J; Orlova A
    Cells; 2018 Oct; 7(10):. PubMed ID: 30314301
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of the Therapeutic Potential of a HER3-Binding Affibody Construct TAM-HER3 in Comparison with a Monoclonal Antibody, Seribantumab.
    Orlova A; Bass TZ; Rinne SS; Leitao CD; Rosestedt M; Atterby C; Gudmundsdotter L; Frejd FY; Löfblom J; Tolmachev V; Ståhl S
    Mol Pharm; 2018 Aug; 15(8):3394-3403. PubMed ID: 29995421
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluating the Therapeutic Efficacy of Mono- and Bivalent Affibody-Based Fusion Proteins Targeting HER3 in a Pancreatic Cancer Xenograft Model.
    Leitao CD; Rinne SS; Altai M; Vorontsova O; Dunås F; Jonasson P; Tolmachev V; Löfblom J; Ståhl S; Orlova A
    Pharmaceutics; 2020 Jun; 12(6):. PubMed ID: 32545760
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Affibody-mediated PET imaging of HER3 expression in malignant tumours.
    Rosestedt M; Andersson KG; Mitran B; Tolmachev V; Löfblom J; Orlova A; Ståhl S
    Sci Rep; 2015 Oct; 5():15226. PubMed ID: 26477646
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of a radiocobalt-labelled affibody molecule for imaging of human epidermal growth factor receptor 3 expression.
    Rosestedt M; Andersson KG; Mitran B; Rinne SS; Tolmachev V; Löfblom J; Orlova A; Ståhl S
    Int J Oncol; 2017 Dec; 51(6):1765-1774. PubMed ID: 29039474
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improved contrast of affibody-mediated imaging of HER3 expression in mouse xenograft model through co-injection of a trivalent affibody for in vivo blocking of hepatic uptake.
    Rosestedt M; Andersson KG; Rinne SS; Leitao CD; Mitran B; Vorobyeva A; Ståhl S; Löfblom J; Tolmachev V; Orlova A
    Sci Rep; 2019 May; 9(1):6779. PubMed ID: 31043683
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative evaluation of 111In-labeled NOTA‑conjugated affibody molecules for visualization of HER3 expression in malignant tumors.
    Andersson KG; Rosestedt M; Varasteh Z; Malm M; Sandström M; Tolmachev V; Löfblom J; Ståhl S; Orlova A
    Oncol Rep; 2015 Aug; 34(2):1042-8. PubMed ID: 26059265
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Site-specific radiometal labeling and improved biodistribution using ABY-027, a novel HER2-targeting affibody molecule-albumin-binding domain fusion protein.
    Orlova A; Jonsson A; Rosik D; Lundqvist H; Lindborg M; Abrahmsen L; Ekblad C; Frejd FY; Tolmachev V
    J Nucl Med; 2013 Jun; 54(6):961-8. PubMed ID: 23528382
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Imaging of EGFR expression in murine xenografts using site-specifically labelled anti-EGFR 111In-DOTA-Z EGFR:2377 Affibody molecule: aspect of the injected tracer amount.
    Tolmachev V; Rosik D; Wållberg H; Sjöberg A; Sandström M; Hansson M; Wennborg A; Orlova A
    Eur J Nucl Med Mol Imaging; 2010 Mar; 37(3):613-22. PubMed ID: 19838701
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting Tumor Cells Overexpressing the Human Epidermal Growth Factor Receptor 3 with Potent Drug Conjugates Based on Affibody Molecules.
    Rinne SS; Yin W; Borras AM; Abouzayed A; Leitao CD; Vorobyeva A; Löfblom J; Ståhl S; Orlova A; Gräslund T
    Biomedicines; 2022 May; 10(6):. PubMed ID: 35740315
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of Residualizing Properties of the Radiolabel on Radionuclide Molecular Imaging of HER3 Using Affibody Molecules.
    Rinne SS; Xu T; Dahlsson Leitao C; Ståhl S; Löfblom J; Orlova A; Tolmachev V; Vorobyeva A
    Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32075258
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimization of HER3 expression imaging using affibody molecules: Influence of chelator for labeling with indium-111.
    Rinne SS; Leitao CD; Mitran B; Bass TZ; Andersson KG; Tolmachev V; Ståhl S; Löfblom J; Orlova A
    Sci Rep; 2019 Jan; 9(1):655. PubMed ID: 30679757
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Engineering of a bispecific affibody molecule towards HER2 and HER3 by addition of an albumin-binding domain allows for affinity purification and in vivo half-life extension.
    Malm M; Bass T; Gudmundsdotter L; Lord M; Frejd FY; Ståhl S; Löfblom J
    Biotechnol J; 2014 Sep; 9(9):1215-22. PubMed ID: 24678002
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative Preclinical Evaluation of HER2-Targeting ABD-Fused Affibody
    Liu Y; Vorobyeva A; Xu T; Orlova A; Loftenius A; Bengtsson T; Jonasson P; Tolmachev V; Frejd FY
    Pharmaceutics; 2021 Jun; 13(6):. PubMed ID: 34200197
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of the first
    Honarvar H; Müller C; Cohrs S; Haller S; Westerlund K; Karlström AE; van der Meulen NP; Schibli R; Tolmachev V
    Nucl Med Biol; 2017 Feb; 45():15-21. PubMed ID: 27837664
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Small-animal SPECT/CT of HER2 and HER3 expression in tumor xenografts in athymic mice using trastuzumab Fab-heregulin bispecific radioimmunoconjugates.
    Razumienko EJ; Scollard DA; Reilly RM
    J Nucl Med; 2012 Dec; 53(12):1943-50. PubMed ID: 23096164
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Imaging of platelet-derived growth factor receptor β expression in glioblastoma xenografts using affibody molecule 111In-DOTA-Z09591.
    Tolmachev V; Varasteh Z; Honarvar H; Hosseinimehr SJ; Eriksson O; Jonasson P; Frejd FY; Abrahmsen L; Orlova A
    J Nucl Med; 2014 Feb; 55(2):294-300. PubMed ID: 24408895
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sustained Inhibition of HER3 and EGFR Is Necessary to Induce Regression of HER2-Amplified Gastrointestinal Carcinomas.
    Leto SM; Sassi F; Catalano I; Torri V; Migliardi G; Zanella ER; Throsby M; Bertotti A; Trusolino L
    Clin Cancer Res; 2015 Dec; 21(24):5519-31. PubMed ID: 26296355
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of backbone-cyclized HER2-binding 2-helix affibody molecule for in vivo molecular imaging.
    Honarvar H; Jokilaakso N; Andersson K; Malmberg J; Rosik D; Orlova A; Karlström AE; Tolmachev V; Järver P
    Nucl Med Biol; 2013 Apr; 40(3):378-86. PubMed ID: 23357083
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.